Capital Research Global Investors Sells 6,636 Shares of Novo Nordisk A/S (NYSE:NVO)

Capital Research Global Investors reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,250 shares of the company's stock after selling 6,636 shares during the period. Capital Research Global Investors' holdings in Novo Nordisk A/S were worth $4,136,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in NVO. Victory Capital Management Inc. grew its holdings in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC lifted its position in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock worth $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC grew its position in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after purchasing an additional 30,420 shares during the last quarter. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $86,000. Finally, Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $4,066,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 0.5 %

Shares of NYSE NVO opened at $58.37 on Tuesday. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The business has a fifty day moving average of $75.05 and a two-hundred day moving average of $90.98. The stock has a market cap of $261.94 billion, a PE ratio of 17.74, a PEG ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is currently 49.54%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NVO shares. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Finally, StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.